Individual-related factors associated with treatment adherence among hypertensive patients
Accepted: 19 February 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Background. Currently, some of the most prevalent illnesses are attributable to external sources, such as chronic disorders that threaten people’s health. The goal of the study was to investigate the differences in individual characteristics associated with treatment adherence among hypertension patients. Materials and Methods. In this descriptive cross-sectional study, 176 hypertensive patients who reviewed primary healthcare facilities in Babylon Province were included. Experts were used to ensure the study questionnaire’s validity, and a pilot study was used to ensure its reliability. Using a standardized questionnaire and interviewing methods, data were collected and analyzed. Results. According to the study’s findings, participants’ average ages were 59 (10.86), 67% of them were over 60, 55.1% and 65.3% of them were men and married respectively, nearly half of them had moderate monthly income, the unemployed percentage was 61.9%, and 36.4% had completed their secondary education. Two-thirds, or 70.5%, of hypertension patients, reported poor treatment adherence. Ages 30-59, male patients, married, highincome, and college-educated patients showed significantly better treatment compliance (P<0.05). Conclusions. Every individual characteristic of patients with high blood pressure is regarded as a predictor of therapy adherence. The current study is one of the few in Iraq to evaluate treatment adherence and look into the various elements that may influence it using the survey approach. Future research on the subject of antihypertensive treatment adherence in the hypertensive population in Iraq employing a representative sample, a qualitative methodology, and more factor exploration may offer additional insights.
Mohsen Ibrahim M. Hypertension in developing countries: a major challenge for the future. Curr Hypertens Rep 2018;20:1-10.
Campbell NR, Ordunez P, DiPette DJ, et al. Monitoring and evaluation framework for hypertension programs. A collaboration between the Pan American Health Organization and World Hypertension League. J Clin Hypertens 2018;20:984-90.
Nahimana MR, Nyandwi A, Muhimpundu MA, et al. A population- based national estimate of the prevalence and risk factors associated with hypertension in Rwanda: implications for prevention and control. BMC Pub Health 2018;18:1-11.
Tatsumi Y, Ohkubo T. Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese. Hypertens Res 2017;40:795-806.
Soesanto E, Ramadlan I, Setyawati D, et al. Factors affecting medication adherence in hypertension patients: a literature review. Bali Med J 2021;10:1364-70.
Sabri M, Gheissari A, Mansourian, et al. Essential hypertension in children, a growing worldwide problem. J Res Med Sci: the official journal of Isfahan University of Medical Sciences 2019;24.
Kim MT, Hill MN, Bone LR, et al. Development and testing of the hill-bone compliance to high blood pressure therapy scale. Progr Cardiovasc Nurs 2000;15:90-6.
Wenger NK, Arnold A, Bairey Merz CN, et al. Hypertension across a woman’s life cycle. J Ame Coll Cardiol 2018;71:1797-813.
Harmon G, Lefante J, Krousel-Wood M. Overcoming barriers: the role of providers in improving patient adherence to antihypertensive medications. Curr Opin Cardiol 2006;21:310-5.
Karakurt P, Kaşikçi M. Factors affecting medication adherence in patients with hypertension. J Vasc Nurs 2012;30:118-26.
Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313.
Copyright (c) 2023 the Authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.